Journal of Bone and Mineral Metabolism

, Volume 32, Issue 4, pp 441–446 | Cite as

Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial

  • Tetsuo Nakano
  • Masataka Shiraki
  • Toshitsugu Sugimoto
  • Hideaki Kishimoto
  • Masako Ito
  • Masao Fukunaga
  • Hiroshi Hagino
  • Teruki Sone
  • Tatsuhiko Kuroda
  • Toshitaka Nakamura
Original Article

Abstract

Once-weekly teriparatide (human parathyroid hormone [1–34]) (56.5 μg for 72 weeks) injections provided a vertebral fracture risk reduction in Japanese osteoporotic patients evaluated in the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Using data from the TOWER trial, a subgroup analysis was performed to study the efficacy of once-weekly teriparatide for a variety of baseline clinical risk factors in placebo (n = 281) and teriparatide (n = 261) groups. Significant fracture risk reductions were observed in the subgroups of individuals aged <75 years [relative risk (RR) 0.06, p = 0.007] and ≥75 years (RR 0.32, p = 0.015). A significant risk reduction was observed among patients with prevalent vertebral fracture in the subgroup with 1 (RR 0.08, p = 0.015) or ≥2 (RR 0.29, p = 0.009) prevalent vertebral fractures, and in those with grade 3 deformity (RR 0.26, p = 0.003). Significant risk reduction was observed in the subgroup with lumbar bone mineral density (BMD) < −2.5 SD (RR 0.25, p = 0.035). In the teriparatide group, no incident fracture was observed in the subgroups with a prevalent vertebral fracture number of 0, with grade 0–2 vertebral deformity, or with lumbar BMD ≥2.5 SD. Significant risk reduction was observed in all of the bone turnover marker and estimated glomerular filtration rate subgroups. In conclusion, once-weekly 56.5 μg teriparatide injection reduced the vertebral fracture risk in patients with varying degrees of fracture risk, age, vertebral fracture number and grade, bone turnover level, and renal function.

Keywords

Teriparatide Once-weekly injection Osteoporosis Vertebral fracture 

References

  1. 1.
    Kanis JA, on behalf of the World Health Organisation Scientific Group (2007) Assessment of osteoporosis at the primary health care level. WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf
  2. 2.
    Fujiwara S, Hamaya E, Goto W, Masunari N, Furukawa K, Fukunaga M, Nakamura T, Miyauchi A, Chen P (2011) Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk in Japan. Bone 49:520–525PubMedCrossRefGoogle Scholar
  3. 3.
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077–2082PubMedCrossRefGoogle Scholar
  4. 4.
    McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
  5. 5.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441PubMedCrossRefGoogle Scholar
  6. 6.
    Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47:493–502PubMedCrossRefGoogle Scholar
  7. 7.
    Yamamoto T, Tsujimoto M, Hamaya E, Sowa H (2013) Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis. J Bone Miner Metab 31:199–205PubMedCrossRefGoogle Scholar
  8. 8.
    Marcus R, Wang O, Satterwhite J, Mitlak B (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18–23PubMedCrossRefGoogle Scholar
  9. 9.
    Bouxsein ML, Chen P, Glass EV, Kallmes DF, Delmas PD, Mitlak BH (2009) Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials. J Bone Joint Surg Am 91:1329–1338PubMedCrossRefGoogle Scholar
  10. 10.
    Gallagher JC, Genant HK, Crans GG, Vargas SJ, Krege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 90:1583–1587PubMedCrossRefGoogle Scholar
  11. 11.
    Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH (2007) Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 18:59–68PubMedCrossRefGoogle Scholar
  12. 12.
    Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106PubMedCrossRefGoogle Scholar
  13. 13.
    Imai E, Horio M, Nitta K, Yamagata K, Iseki K et al (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41–50PubMedCrossRefGoogle Scholar
  14. 14.
    Genant HK, Jergas M, Palermo L, Nevitt M, Valentin RS, Black D, Cummings SR (1996) Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The study of Osteoporotic Fractures Research Group. J Bone Miner Res 11:984–996PubMedCrossRefGoogle Scholar
  15. 15.
    Kado DM, Duong T, Stone KL, Ensrud KE, Nevitt MC, Greendale GA, Cummings SR (2003) Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int 14:589–594PubMedCrossRefGoogle Scholar
  16. 16.
    Hallberg I, Bachrach-Lindstrom M, Hammerby S, Toss G, Ek AC (2009) Health-related quality of life after vertebral or hip fracture: a seven-year follow-up study. BMC Musculoskel Disord 10:135CrossRefGoogle Scholar
  17. 17.
    Wustrack R, Seeman E, Bucci-Rechtweg C, Burch S, Palermo L, Black DM (2012) Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. Osteoporos Int 23:53–58PubMedCrossRefGoogle Scholar
  18. 18.
    Nevitt MC, Cummings SR, Stone KL, Palermo L, Black DM, Bauer DC, Genant HK, Hochberg MC, Ensrud KE, Hillier TA, Cauley JA (2005) Risk factors for a first-incident radiographic vertebral fracture in women ≥65 years of age: the study of osteoporotic fractures. J Bone Miner Res 20:131–140PubMedCrossRefGoogle Scholar
  19. 19.
    Ross PD, Davis JW, Epstein RS, Wasnich RD (1991) Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114:919–923PubMedCrossRefGoogle Scholar
  20. 20.
    Kaji H, Yamauchi M, Yamaguchi T, Shigematsu T, Sugimoto T (2010) Mild renal dysfunction is a risk factor for a decrease in bone mineral density and vertebral fractures in Japanese postmenopausal women. J Clin Endocrinol Metab 95:4635–4642PubMedCrossRefGoogle Scholar
  21. 21.
    Cockerill W, Ismail AA, Cooper C, Matthis C, Raspe H, Silman AJ, O’Neill TW (2000) Does location of vertebral deformity within the spine influence back pain and disability? Ann Rheum Dis 59:368–371PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392PubMedCrossRefGoogle Scholar
  23. 23.
    Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM (2007) Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 357:2189–2194PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2013

Authors and Affiliations

  • Tetsuo Nakano
    • 1
  • Masataka Shiraki
    • 2
  • Toshitsugu Sugimoto
    • 3
  • Hideaki Kishimoto
    • 4
  • Masako Ito
    • 5
  • Masao Fukunaga
    • 6
  • Hiroshi Hagino
    • 7
  • Teruki Sone
    • 8
  • Tatsuhiko Kuroda
    • 9
  • Toshitaka Nakamura
    • 10
  1. 1.Tamana Central HospitalTamanaJapan
  2. 2.Research Institute and Practice for Involutional DiseasesAzuminoJapan
  3. 3.Internal Medicine 1Shimane University Faculty of MedicineIzumoJapan
  4. 4.Nojima HospitalKurayoshiJapan
  5. 5.Medical Work-Life-Balance CenterNagasaki University HospitalNagasakiJapan
  6. 6.Kawasaki Medical SchoolKurashikiJapan
  7. 7.School of Health Science and Rehabilitation Division, Faculty of MedicineTottori UniversityYonagoJapan
  8. 8.Department of Nuclear MedicineKawasaki Medical SchoolKurashikiJapan
  9. 9.Project for Bone Metabolic DiseaseAsahi Kasei Pharma CorporationTokyoJapan
  10. 10.National Center for Global Health and MedicineTokyoJapan

Personalised recommendations